PL1831699T3 - Oznaczanie lipokaliny neutrofilowej związanej z żelatynazą (NGAL) jako markera diagnostycznego dla zaburzeń nerek - Google Patents

Oznaczanie lipokaliny neutrofilowej związanej z żelatynazą (NGAL) jako markera diagnostycznego dla zaburzeń nerek

Info

Publication number
PL1831699T3
PL1831699T3 PL05820913T PL05820913T PL1831699T3 PL 1831699 T3 PL1831699 T3 PL 1831699T3 PL 05820913 T PL05820913 T PL 05820913T PL 05820913 T PL05820913 T PL 05820913T PL 1831699 T3 PL1831699 T3 PL 1831699T3
Authority
PL
Poland
Prior art keywords
ngal
determination
renal disorders
neutrophil gelatinase
associated lipocalin
Prior art date
Application number
PL05820913T
Other languages
English (en)
Inventor
Lars Otto Uttenthal
Margarita Ghiglione Juanes
Kristian Bangert
Original Assignee
Antibodyshop As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36011033&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1831699(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Antibodyshop As filed Critical Antibodyshop As
Publication of PL1831699T3 publication Critical patent/PL1831699T3/pl

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96486—Metalloendopeptidases (3.4.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL05820913T 2004-12-20 2005-12-20 Oznaczanie lipokaliny neutrofilowej związanej z żelatynazą (NGAL) jako markera diagnostycznego dla zaburzeń nerek PL1831699T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US63750304P 2004-12-20 2004-12-20
US71930705P 2005-09-21 2005-09-21
EP05820913A EP1831699B1 (en) 2004-12-20 2005-12-20 Determination of neutrophil gelatinase-associated lipocalin (ngal) as a diagnostic marker for renal disorders
PCT/DK2005/000806 WO2006066587A1 (en) 2004-12-20 2005-12-20 Determination of neutrophil gelatinase-associated lipocalin (ngal) as a diagnostic marker for renal disorders

Publications (1)

Publication Number Publication Date
PL1831699T3 true PL1831699T3 (pl) 2010-04-30

Family

ID=36011033

Family Applications (2)

Application Number Title Priority Date Filing Date
PL05820913T PL1831699T3 (pl) 2004-12-20 2005-12-20 Oznaczanie lipokaliny neutrofilowej związanej z żelatynazą (NGAL) jako markera diagnostycznego dla zaburzeń nerek
PL18195687T PL3489689T3 (pl) 2004-12-20 2005-12-20 Oznaczanie lipokaliny neutrofilowej związanej z żelatynazą (NGAL) jako markera diagnostycznego dla zaburzeń zaburzenie nerki

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL18195687T PL3489689T3 (pl) 2004-12-20 2005-12-20 Oznaczanie lipokaliny neutrofilowej związanej z żelatynazą (NGAL) jako markera diagnostycznego dla zaburzeń zaburzenie nerki

Country Status (18)

Country Link
US (3) US20090170143A1 (pl)
EP (4) EP3489689B1 (pl)
JP (1) JP4741603B2 (pl)
KR (1) KR100971305B1 (pl)
CN (1) CN101163971B (pl)
AT (1) ATE448484T1 (pl)
AU (1) AU2005318689B2 (pl)
CA (1) CA2591113C (pl)
DE (1) DE602005013288D1 (pl)
DK (3) DK1831699T3 (pl)
ES (4) ES2703434T3 (pl)
HK (1) HK1105454A1 (pl)
IL (1) IL183872A (pl)
NZ (1) NZ555926A (pl)
PL (2) PL1831699T3 (pl)
SI (1) SI1831699T1 (pl)
WO (1) WO2006066587A1 (pl)
ZA (1) ZA200705776B (pl)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5392980B2 (ja) * 2003-03-27 2014-01-22 チルドレンズ ホスピタル メディカル センター 早発型の腎尿細管細胞障害を検出するための方法およびキット
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
US20080090304A1 (en) * 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
US20090197280A1 (en) 2006-05-30 2009-08-06 Kristian Bangert Methods and Devices for Rapid Assessment of Severity of Injury
EP2064553B2 (en) * 2006-08-07 2023-06-07 Antibodyshop A/S Diagnostic test to exclude significant renal injury
WO2008061149A2 (en) * 2006-11-14 2008-05-22 Biosite Incorporated Methods and compositions for diagnosis and prognosis of renal artery stenosis
EP2095107B1 (en) 2006-11-14 2014-07-02 Alere San Diego, Inc. Methods for risk assignment
EP2121965B1 (en) * 2006-12-20 2013-11-20 Antibodyshop A/S Assessment of patients with sepsis to determine a requirement for therapeutic intervention with an antiinflammatory and/or anticoagulatory agent
WO2008103815A2 (en) * 2007-02-23 2008-08-28 Predictive Biosciences Corporation Clinical intervention directed diagnostic methods
EP2137538B1 (en) 2007-03-21 2014-04-09 Bioporto Diagnostics A/s Diagnostic test for renal injury
US8846036B2 (en) 2007-10-19 2014-09-30 Abbott Laboratories Antibodies that bind to mammalian NGAL and uses thereof
US20090123946A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Immunoassays and kits for the detection of ngal
WO2009059259A2 (en) * 2007-10-31 2009-05-07 Children's Hospital Medical Center Detection of worsening renal disease in subjects with systemic lupus erythematosus
WO2009062520A1 (en) * 2007-11-15 2009-05-22 Bioporto Diagnostics A/S Diagnostic use of individual molecular forms of a biomarker
US8592170B2 (en) * 2008-03-12 2013-11-26 The Trustees Of Columbia University In The City Of New York High molecular weight Ngal as a biomarker for chronic kidney disease
US7977110B2 (en) * 2008-06-02 2011-07-12 Children's Hospital Medical Center Method for distinguishing between kidney dysfunctions
NZ591437A (en) 2008-08-28 2013-07-26 Astute Medical Inc Methods and compositions for diagnosis and prognosis of renal injury and renal failure
US20100105150A1 (en) * 2008-10-24 2010-04-29 Abbott Laboratories Isolated human autoantibodies to neutrophil gelatinase-associated lipocalin (ngal) and methods and kits for the detection of human autoantibodies to ngal
WO2010054025A1 (en) 2008-11-05 2010-05-14 Abbott Laboratories Neutrophil gelatinase-associated lipocalin (ngal) protein isoforms enriched from urine and recombinant chinese hamster ovary (cho) cells and related compositions, antibodies, and methods of enrichment, analysis and use
CA2744434C (en) * 2008-11-21 2017-10-03 Phadia Ab Methods, devices and kits for detecting or monitoring acute kidney injury
US20100233740A1 (en) * 2009-02-12 2010-09-16 Jonathan Barasch Use of urinary ngal to distinguish kidney disease and predict mortality in subjects with cirrhosis
US20100233739A1 (en) * 2009-02-12 2010-09-16 Jonathan Barasch Use of urinary ngal to diagnose unilateral and bilateral urinary obstruction
ES2350078B1 (es) * 2009-05-19 2011-11-15 Consejo Superior De Investigaciones Científicas (Csic) Celula del smf modificada geneticamente para sobreexpresar ngal y su uso como medicamento
US20120214177A1 (en) * 2009-06-17 2012-08-23 The Trustees Of Columbia University In The City Of New York Methods and compositions for diagnosis of urosepsis and urinary tract infection
EP2462445A1 (en) * 2009-08-07 2012-06-13 Rules-Based Medicine, Inc. Devices for detecting renal disorders
JP5775874B2 (ja) * 2009-08-28 2015-09-09 アスチュート メディカル，インコーポレイテッド 腎損傷および腎不全の診断および予後診断のための方法ならびに組成物
WO2011053832A1 (en) * 2009-10-29 2011-05-05 The Trustees Of Columbia University In The City Of New York Use of urinary ngal to diagnose sepsis in very low birth weight infants
US20110195903A1 (en) * 2009-12-15 2011-08-11 Adra Chaker N Methods and compositions for detecting recessive familial fsgs and uses thereof
CN102072960A (zh) * 2010-03-29 2011-05-25 武汉生之源生物科技有限公司 一种样本中中性粒细胞明胶酶相关脂质运载蛋白的检测方法
WO2011149962A1 (en) 2010-05-24 2011-12-01 The Trustees Of Columbia University In The City Of New York Mutant ngal proteins and uses thereof
EP2625524A4 (en) * 2010-10-07 2014-05-07 Astute Medical Inc METHOD AND COMPOSITIONS FOR DIAGNOSIS AND FORECASTING kidney injury and kidney insufficiency
CN102253217B (zh) * 2011-04-07 2013-08-07 武汉生之源生物科技有限公司 一种胶乳颗粒增强型中性粒细胞明胶酶相关脂质运载蛋白检测试剂盒
TW201250248A (en) * 2011-04-25 2012-12-16 Kyowa Medex Co Ltd Prognostication method of renal failure
NL2007112C2 (en) 2011-07-14 2013-01-15 Brainlabs B V Novel diagnostic method for diagnosing depression and monitoring therapy effectiveness.
US20130062516A1 (en) * 2011-09-09 2013-03-14 Hsien-Shou Kuo Diganosis of a renal disease by oxygen and hydrogen isotopes in a biological sample
GB2519208A (en) * 2012-01-11 2015-04-15 Craig Venter Inst J Metaproteomic method for diagnosis of bacteriuria, urogenital tract and kidney infections from urinary pellet samples
CN102662064A (zh) * 2012-04-26 2012-09-12 苏州照康生物技术有限公司 检测中性粒细胞明胶酶相关脂质运载蛋白的免疫比浊试剂盒及其制备方法
EP2925337B1 (en) 2012-11-21 2019-07-03 The Trustees of Columbia University in the City of New York Mutant ngal proteins and uses thereof
CN203441604U (zh) 2013-02-15 2014-02-19 通用电气公司 用于降低燃气涡轮系统中的背压的系统
US9488663B2 (en) 2013-03-14 2016-11-08 Abbott Point Of Care Inc. Electrochemical methods and devices for amending urine samples for immunosensor detection
US9651547B2 (en) 2013-03-14 2017-05-16 Abbott Point Of Care Inc. Electrochemical methods and devices for amending urine samples for immunosensor detection
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
KR101590622B1 (ko) 2013-10-24 2016-02-01 (주)메디컬그룹베스티안 화상 중증도 판단 방법
DK3143037T3 (da) 2014-05-16 2021-09-20 Protagonist Therapeutics Inc Alpha4beta7-integrin-thioether-peptidantagonister
RU2736637C9 (ru) 2014-07-17 2021-02-08 Протагонист Терепьютикс, Инк. Пептидные ингибиторы рецептора интерлейкина-23 для перорального приема и их применение для лечения воспалительных заболеваний кишечника
JP6788586B2 (ja) 2014-11-19 2020-11-25 コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． Ｈｎｌを用いる診断方法
CN104502596A (zh) * 2014-12-23 2015-04-08 温州医科大学 一种慢性肾病诊断试剂盒
KR101657881B1 (ko) * 2015-03-16 2016-09-19 대구한의대학교산학협력단 타깃 바이오마커에 고특이적이며 고선택적 결합이 가능한 펩타이드 프로브 및 그를 이용한 급성 및 만성 신장질환 조기진단용 바이오칩
EP3334498B1 (en) 2015-08-12 2023-06-07 The Trustees of Columbia University in the City of New York Methods of treating volume depletion and kidney injury
EP3184116B1 (en) 2015-12-23 2020-09-16 National Taiwan Normal University Neutrophil gelatinase-associated lipocalin for use in prevention or treatment of polycystic kidney disease
TWI581802B (zh) 2015-12-23 2017-05-11 國立臺灣師範大學 嗜中性白血球膠原蛋白質酶相關疏水性蛋白質之製藥用途
CA3009834A1 (en) 2015-12-30 2017-07-06 Protagonist Therapeutics, Inc. Analogues of hepcidin mimetics with improved in vivo half lives
US20200064357A1 (en) * 2016-11-09 2020-02-27 Protagonist Therapeutics, Inc. Methods for determining and monitoring gastrointestinal inflammation
WO2019157268A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
KR102094608B1 (ko) * 2018-08-08 2020-04-23 고려대학교 산학협력단 혈액암의 분류 및 예후 판단에 필요한 정보를 제공하는 방법
CN109781990A (zh) * 2018-12-25 2019-05-21 无锡市人民医院 一种β-痕迹蛋白检测试剂盒及制备方法
KR102293024B1 (ko) * 2020-02-07 2021-08-24 고려대학교 산학협력단 혈액 종양 질환 특이적 바이오마커

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3635091A (en) * 1970-08-31 1972-01-18 Frederick D Linzer Midstream urine specimen and fractional fluid collectors
IT1074038B (it) * 1976-08-05 1985-04-17 Simes Esteri della epinina
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4357343A (en) * 1981-06-26 1982-11-02 Baxter Travenol Laboratories, Inc. Nutritional composition for management of renal failure
US4659678A (en) * 1982-09-29 1987-04-21 Serono Diagnostics Limited Immunoassay of antigens
US4640909A (en) * 1985-05-07 1987-02-03 J. T. Baker Chemical Company Bonded phase of silica and carboalkoxyalkyl silanes for solid phase extraction
US5939272A (en) * 1989-01-10 1999-08-17 Biosite Diagnostics Incorporated Non-competitive threshold ligand-receptor assays
US5200319A (en) * 1989-10-27 1993-04-06 The General Hospital Corporation Diagnosis of glomerulonephritis
JP2912413B2 (ja) * 1990-03-28 1999-06-28 東亜医用電子株式会社 粒度分布作成方法
US5405832A (en) * 1991-11-27 1995-04-11 Immtech International Inc. Method of treating non-streptococcal bacterial infections
US5273961A (en) * 1992-09-22 1993-12-28 Genentech, Inc. Method of prophylaxis of acute renal failure
SE9401351D0 (sv) * 1994-04-21 1994-04-21 Venge A method for diagnosis
US5552313A (en) * 1994-11-21 1996-09-03 Kansas University DNA encoding mouse phosphotriesterase-related protein
US5750345A (en) * 1995-10-31 1998-05-12 Evanston Hospital Corporation Detection of human α-thalassemia mutations and their use as predictors of blood-related disorders
US5627034A (en) * 1995-12-05 1997-05-06 Wisconsin Alumni Research Foundation Assay for carcinoma proliferative status by measuring NGAL expression level
EA004402B1 (ru) * 1996-05-24 2004-04-29 Байоджен, Инк. Модуляторы регенерации тканей
US6020163A (en) * 1997-08-06 2000-02-01 Zymogenetics, Inc. Lipocalin homolog
US6309888B1 (en) * 1998-09-04 2001-10-30 Leuven Research & Development Vzw Detection and determination of the stages of coronary artery disease
AUPP784398A0 (en) * 1998-12-21 1999-01-21 Monash University Kidney disease detection and treatment
WO2000078919A1 (en) * 1999-06-18 2000-12-28 Michigan State University Method and apparatus for the detection of volatile products in a sample
US6762032B1 (en) * 1999-08-23 2004-07-13 Biocrystal, Ltd. Compositions, assay kits, and methods for use related to a disease condition comprising multiple sclerosis and/or a pro-MS immune response
AU2001293964B2 (en) * 2000-10-03 2007-06-14 Rowett Research Institute Method of assaying pyrrole-containing biological compounds
US6564385B2 (en) * 2000-10-06 2003-05-20 Mccarthy Daniel J. Handling device
AU1169702A (en) * 2000-10-13 2002-04-22 Childrens Medical Center Non-invasive enzyme screen for tissue remodelling-associated conditions
FI20010019A (fi) * 2001-01-05 2002-07-06 Biohit Oyj Menetelmä atrofisen diagnostisoimiseksi
US7713705B2 (en) * 2002-12-24 2010-05-11 Biosite, Inc. Markers for differential diagnosis and methods of use thereof
US20040203083A1 (en) * 2001-04-13 2004-10-14 Biosite, Inc. Use of thrombus precursor protein and monocyte chemoattractant protein as diagnostic and prognostic indicators in vascular diseases
DE10120614A1 (de) 2001-04-26 2002-10-31 Sms Demag Ag Kühlplatte
AU2002305394A1 (en) * 2001-05-04 2002-11-18 Biosite, Inc. Diagnostic markers of acute coronary syndromes and methods of use thereof
WO2003029462A1 (en) * 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
US20030119209A1 (en) * 2001-12-21 2003-06-26 Kaylor Rosann Marie Diagnostic methods and devices
US6986995B2 (en) * 2002-02-28 2006-01-17 Prometheus Laboratories, Inc. Methods of diagnosing liver fibrosis
US6847451B2 (en) * 2002-05-01 2005-01-25 Lifescan, Inc. Apparatuses and methods for analyte concentration determination
GB0215509D0 (en) * 2002-07-04 2002-08-14 Novartis Ag Marker genes
US7056702B2 (en) * 2002-12-16 2006-06-06 Kimberly Clark Co Detecting lipocalin
JP5392980B2 (ja) * 2003-03-27 2014-01-22 チルドレンズ ホスピタル メディカル センター 早発型の腎尿細管細胞障害を検出するための方法およびキット
US20050272101A1 (en) * 2004-06-07 2005-12-08 Prasad Devarajan Method for the early detection of renal injury
WO2005107793A2 (en) * 2004-05-06 2005-11-17 The Trustees Of Columbia University Ngal for reduction and amelioration of ischemic and nephrotoxic injuries
US20070037232A1 (en) * 2005-03-31 2007-02-15 Barasch Jonathan M Detection of NGAL in chronic renal disease
US20080090304A1 (en) * 2006-10-13 2008-04-17 Barasch Jonathan Matthew Diagnosis and monitoring of chronic renal disease using ngal
WO2007098102A2 (en) * 2006-02-17 2007-08-30 Children's Medical Center Corporation Free ngal as a biomarker for cancer
US20080061149A1 (en) * 2006-09-11 2008-03-13 Colin Tanner Proximity payment card with security interlock
US20090124022A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Antibodies that bind to mammalian ngal and uses thereof
US20090123970A1 (en) * 2007-10-19 2009-05-14 Abbott Laboratories Glycosylated mammalian ngal and use thereof
DE102008025144A1 (de) * 2008-05-26 2009-12-03 Siemens Aktiengesellschaft Anordnung zur Erhöhung der Lese- und Schreibsicherheit von RFID-Labeln

Also Published As

Publication number Publication date
EP2128625A3 (en) 2010-07-07
EP3489689B1 (en) 2020-06-17
ES2622467T3 (es) 2017-07-06
US20090170143A1 (en) 2009-07-02
JP4741603B2 (ja) 2011-08-03
EP3208616A1 (en) 2017-08-23
NZ555926A (en) 2008-11-28
CA2591113A1 (en) 2006-06-29
IL183872A (en) 2010-11-30
SI1831699T1 (sl) 2010-03-31
DK1831699T3 (da) 2010-03-15
EP3208616B1 (en) 2018-09-26
EP1831699A1 (en) 2007-09-12
US20150132772A1 (en) 2015-05-14
HK1105454A1 (en) 2008-02-15
CA2591113C (en) 2022-06-21
KR100971305B9 (ko) 2022-07-11
US20160003851A1 (en) 2016-01-07
IL183872A0 (en) 2007-10-31
DE602005013288D1 (de) 2010-05-06
AU2005318689A1 (en) 2006-06-29
EP1831699B1 (en) 2009-11-11
ES2818028T3 (es) 2021-04-09
PL3489689T3 (pl) 2020-11-16
ZA200705776B (en) 2007-10-31
ES2336345T3 (es) 2010-04-12
JP2008524610A (ja) 2008-07-10
EP3489689A1 (en) 2019-05-29
AU2005318689B2 (en) 2010-08-19
ES2703434T3 (es) 2019-03-08
DK2128625T3 (en) 2017-05-01
CN101163971A (zh) 2008-04-16
EP2128625A2 (en) 2009-12-02
WO2006066587A1 (en) 2006-06-29
EP2128625B1 (en) 2017-01-25
DK3489689T3 (da) 2020-09-07
KR100971305B1 (ko) 2010-07-20
KR20070108158A (ko) 2007-11-08
CN101163971B (zh) 2013-03-20
ATE448484T1 (de) 2009-11-15

Similar Documents

Publication Publication Date Title
IL183872A0 (en) Determination of neutrophil gelatinase-associated lipocalin (ngal) as a diagnostic marker for renal disorders
DE602007011566D1 (en) Ankheit
WO2008148072A3 (en) Disease-associated genetic variations and methods for obtaining and using same
WO2007016367A3 (en) Neoplastic disease-related methods, kits, systems and databases
PL2035835T3 (pl) Sposoby szybkiej oceny ciężkości urazu
MX2009011494A (es) Marcadores de enfermedades.
WO2007117444A3 (en) Protein detection by aptamers
WO2007056523A3 (en) Methods for diagnosing and monitoring the progression of cancer
WO2008061149A3 (en) Methods and compositions for diagnosis and prognosis of renal artery stenosis
ATE554389T1 (de) Apex als marker für lungenkrebs
KR100711046B1 (ko) 대장암에 대한 마커로서의 니코틴아미드ｎ―메틸트랜스퍼라아제의 용도
WO2009113814A3 (ko) 간암 진단용 단백질성 마커
WO2006092729A3 (en) Novel biomarkers for diagnosis and/or prognosis or prognosis of neoplasias in animals
WO2006099543A3 (en) Methods for assessing antibody-mediated cytotoxicity
WO2005121366A8 (ja) 遺伝子マーカー及びその利用
HK1136873A1 (en) Use of nnmt as a marker for lung cancer
WO2008131261A3 (en) Peptide biomarkers of cardiovascular disease
BRPI0512655A (pt) bioexame de rna
WO2007075672A3 (en) Prognostic cancer markers
WO2006119264A3 (en) Antibodies against histone modifications for clinical diagnosis and prognosis of cancer
MX2011007810A (es) Biomarcadores asociados con nefropatia.
WO2008099608A1 (ja) 炎症性腸疾患の診断方法
NZ590993A (en) Dual specificity phosphatase 1 protein (DUSP1) for diagnosis and prognosis of skin cancer
WO2010043393A8 (en) Use of biglycan in the assessment of heart failure
WO2004038377A3 (en) Method for diagnosing renal diseases or predispositions